Exagen inc. expands in-network benefit with additional 22.7 million lives

San diego, march 22, 2022 (globe newswire) -- exagen inc. (nasdaq: xgn), a leading provider of autoimmune testing solutions, announced today that avise® tests will soon surpass 90 million lives as an in-network benefit for patients. effective june 1, 2022, avise test offerings become an in-network, covered benefit with centene corporation, including its subsidiary wellcare health plans, providing enhanced care to over 22.7 million members.
XGN Ratings Summary
XGN Quant Ranking